BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badra S, Ruchi R, Zeng X, Gordan L, Shah CV. Immune checkpoint inhibitor associated renally limited thrombotic microangiopathy - a clinical dilemma. Eur J Cancer 2022;169:126-30. [PMID: 35561455 DOI: 10.1016/j.ejca.2022.03.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwak SH, Shah CV. A brief review of renal-limited thrombotic microangiopathy associated with immune checkpoint inhibitors. Journal of Onco-Nephrology 2023. [DOI: 10.1177/23993693221147769] [Reference Citation Analysis]
2 Onwuemene OA, Nnoruka CI, Patriquin CJ, Connelly-Smith LS. Therapeutic plasma exchange in the management of immune checkpoint inhibitor-associated immune-related adverse effects: A review. Transfusion 2022. [PMID: 36134464 DOI: 10.1111/trf.17114] [Reference Citation Analysis]
3 . Pembrolizumab. Reactions Weekly 2022;1910:394-394. [DOI: 10.1007/s40278-022-17229-z] [Reference Citation Analysis]